Not provided
Not provided
Not provided
Not provided
Not provided
Unable to recruit the adequate number of subjects
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will compare 2 different sedation drugs (Ketamine and Midazolam) when they are used with another sedating medicine called Dexmedetomidine for MRI sedation. This study hopes to measure the impact each drug has on what happens during and after MRI sedation with Dexmedetomidine
The will be a randomized, double-blind, prospective study. All patients referred to UCSS for brain MRI and for whom dexmedetomidine would otherwise be the sedation regimen of choice will be eligible for enrollment. The investigators propose to limit the study to patients undergoing only brain MRI as these studies are of a predictable length (25-30 minutes); therefore the sedation regimen can be more easily standardized. Parents of eligible patients would be approached prior to or during the pre-sedation assessment and told about the study and, if they agree to enroll, informed consent would be obtained. Assent will be obtained from children 7 years of age and greater, if they are otherwise developmentally capable of giving assent. The goal is to enroll 50 subjects (25 per treatment group) which would be sufficient to detect a 25% or greater difference in the mean maximal heart rate or blood pressure decrease from baseline between the 2 groups.
Following consent, subjects would be randomized to be sedated with either midazolam-dexmedetomidine or ketamine-dexmedetomidine and, upon achieving an appropriate depth of sedation, undergo their MRI. Monitoring during the MRI and subsequent recovery would occur in compliance with the current Norton Children's Hospital Sedation policy. Recovery-related behavior would be assessed using the Pediatric Anesthesia Emergence Delirium Scale.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Dexmedetomidine and Ketamine | Experimental | Subjects will already be getting Dexmedetomidine and Ketamine for their routine care. |
|
| Dexmedetomidine and Midazolam | Active Comparator | Subjects will already be getting Dexmedetomidine and Midazolam for their routine care. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketamine | Drug | Sedation medication |
| |
| Midazolam |
| Measure | Description | Time Frame |
|---|---|---|
| The Number of Participants With Hypotension and/or Bradycardia During Sedation and Recovery (Generally 2-3 Hours) | number of participants developing hypotension and or bradycardia | a total of 2-3 hours during sedation and recovery. |
| Measure | Description | Time Frame |
|---|---|---|
| Percent Change in Heart Rate From Baseline | Change in heart rate from baseline. | during sedation and recovery (generally 2-3 hours) |
| Percent Change in Blood Pressure From Baseline | Change in blood pressure from baseline. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Previous adverse reaction to dexmedetomidine or clonidine
Current use of clonidine as a routine medication
Concurrent use of a heart-rate decreasing medication (digoxin, propranolol)
Contraindication to ketamine use
Planned additional procedure during the sedation encounter (non-brain MRI, lumbar puncture, EEG etc)
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| John W. Berkenbosch, M.D. | University of Louisville | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Louisville | Louisville | Kentucky | 40202 | United States |
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Dexmedetomidine and Ketamine | Subjects will already be getting Dexmedetomidine and Ketamine for their routine care. Ketamine Dexmedetomidine |
| FG001 | Dexmedetomidine and Midazolam | Subjects will already be getting Dexmedetomidine and Midazolam for their routine care. Midazolam Dexmedetomidine |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
21 subjects enrolled however, 1 subject's data was on paper archived and not available to perform demographic analysis therefore is not included here.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Dexmedetomidine and Ketamine | Subjects will already be getting Dexmedetomidine and Ketamine for their routine care. Ketamine Dexmedetomidine |
| BG001 | Dexmedetomidine and Midazolam |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | The Number of Participants With Hypotension and/or Bradycardia During Sedation and Recovery (Generally 2-3 Hours) | number of participants developing hypotension and or bradycardia | Posted | Count of Participants | Participants | a total of 2-3 hours during sedation and recovery. |
|
24 hours
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Dexmedetomidine and Ketamine | Subjects will already be getting Dexmedetomidine and Ketamine for their routine care. Ketamine Dexmedetomidine |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| John W. Berkenbosch | University of Louisville | 502-852-3720 | john.berkenbosch@louisville.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Apr 2, 2014 | Feb 1, 2021 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D007649 | Ketamine |
| D008874 | Midazolam |
| D020927 | Dexmedetomidine |
| ID | Term |
|---|---|
| D003510 | Cyclohexanes |
| D003516 | Cycloparaffins |
| D006840 | Hydrocarbons, Alicyclic |
| D006844 | Hydrocarbons, Cyclic |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
Sedation medication |
|
| Dexmedetomidine | Drug | Sedation medication |
|
| during sedation and recovery (generally 2-3 hours) |
| The Number of Participants With Adverse Recovery-related Behaviors During Sedation Recovery | This study will compare the number of participants with adverse recovery-related behaviors, based on the PAED scores, between the 2 treatment arms. | Recovery-related behaviors will be specifically measured using the "Pediatric Anesthesia Emergence Delirium (PAED)" scale every 5 minutes from procedure completion until sedation recovery is complete (usually less than 2 hrs) |
Subjects will already be getting Dexmedetomidine and Midazolam for their routine care.
Midazolam
Dexmedetomidine
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Age, Continuous | Collected: age and sex, weight, BMI, primary diagnosis, and reason for MRI race/ethnicity not collected per protocol | Mean | Standard Deviation | months |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Race data was not collected. | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| BMI | Mean | Standard Deviation | kilogram per meter squared |
|
| Primary Diagnosis | Number | participants |
|
| MRI Indication | Count of Participants | Participants |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Secondary | Percent Change in Heart Rate From Baseline | Change in heart rate from baseline. | Posted | Mean | Standard Deviation | percent change from baseline | during sedation and recovery (generally 2-3 hours) |
|
|
|
|
| Secondary | Percent Change in Blood Pressure From Baseline | Change in blood pressure from baseline. | Posted | Mean | Standard Deviation | percent change from baseline | during sedation and recovery (generally 2-3 hours) |
|
|
|
|
| Secondary | The Number of Participants With Adverse Recovery-related Behaviors During Sedation Recovery | This study will compare the number of participants with adverse recovery-related behaviors, based on the PAED scores, between the 2 treatment arms. | Posted | Count of Participants | Participants | Recovery-related behaviors will be specifically measured using the "Pediatric Anesthesia Emergence Delirium (PAED)" scale every 5 minutes from procedure completion until sedation recovery is complete (usually less than 2 hrs) |
|
|
|
| 0 |
| 7 |
| 0 |
| 7 |
| 0 |
| 7 |
| EG001 | Dexmedetomidine and Midazolam | Subjects will already be getting Dexmedetomidine and Midazolam for their routine care. Midazolam Dexmedetomidine | 0 | 13 | 0 | 13 | 0 | 13 |
Not provided
Not provided
Not provided
| D006838 |
| Hydrocarbons |
| D009930 | Organic Chemicals |
| D001569 | Benzodiazepines |
| D001552 | Benzazepines |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| Native Hawaiian or Other Pacific Islander |
|
| Black or African American |
|
| White |
|
| More than one race |
|
| Unknown or Not Reported |
|